BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Z, Zhu WG. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int J Biol Sci. 2014;10:757-770. [PMID: 25013383 DOI: 10.7150/ijbs.9067] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu L, Zhao WM, Yang XH, Sun ZQ, Jin HZ, Lei C, Jin B, Wang HJ. Effect of inhibiting Beclin-1 expression on autophagy, proliferation and apoptosis in colorectal cancer. Oncol Lett 2017;14:4319-24. [PMID: 28989537 DOI: 10.3892/ol.2017.6687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
2 Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med 2016;6:a026831. [PMID: 27599530 DOI: 10.1101/cshperspect.a026831] [Cited by in Crossref: 374] [Cited by in F6Publishing: 339] [Article Influence: 62.3] [Reference Citation Analysis]
3 Fang K, Dong G, Li Y, He S, Wu Y, Wu S, Wang W, Sheng C. Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors. ACS Med Chem Lett 2018;9:312-7. [PMID: 29670692 DOI: 10.1021/acsmedchemlett.7b00487] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
4 Kiweler N, Brill B, Wirth M, Breuksch I, Laguna T, Dietrich C, Strand S, Schneider G, Groner B, Butter F, Heinzel T, Brenner W, Krämer OH. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. Arch Toxicol 2018;92:2227-43. [DOI: 10.1007/s00204-018-2229-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
5 Li Y, Li Z, Dong L, Tang M, Zhang P, Zhang C, Cao Z, Zhu Q, Chen Y, Wang H, Wang T, Lv D, Wang L, Zhao Y, Yang Y, Wang H, Zhang H, Roeder RG, Zhu WG. Histone H1 acetylation at lysine 85 regulates chromatin condensation and genome stability upon DNA damage. Nucleic Acids Res 2018;46:7716-30. [PMID: 29982688 DOI: 10.1093/nar/gky568] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
6 Kolbinger FR, Koeneke E, Ridinger J, Heimburg T, Müller M, Bayer T, Sippl W, Jung M, Gunkel N, Miller AK, Westermann F, Witt O, Oehme I. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. Arch Toxicol 2018;92:2649-64. [PMID: 29947893 DOI: 10.1007/s00204-018-2234-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
7 Ko H, Jeong MH, Jeon H, Sung GJ, So Y, Kim I, Son J, Lee SW, Yoon HG, Choi KC. Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage. Oncotarget 2015;6:9970-84. [PMID: 25991668 DOI: 10.18632/oncotarget.3667] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
8 Al-amily DH, Hassan Mohammed M. Design, Synthesis, and Docking Study of Acyl Thiourea Derivatives as Possible Histone Deacetylase Inhibitors with a Novel Zinc Binding Group. Sci Pharm 2019;87:28. [DOI: 10.3390/scipharm87040028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
9 Barbaraci C, Giurdanella G, Leotta CG, Longo A, Amata E, Dichiara M, Pasquinucci L, Turnaturi R, Prezzavento O, Cacciatore I, Zuccarello E, Lupo G, Pitari GM, Anfuso CD, Marrazzo A. Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma. J Med Chem 2021;64:13622-32. [PMID: 34477381 DOI: 10.1021/acs.jmedchem.1c00995] [Reference Citation Analysis]
10 Chiu CF, Chin HK, Huang WJ, Bai LY, Huang HY, Weng JR. Induction of Apoptosis and Autophagy in Breast Cancer Cells by a Novel HDAC8 Inhibitor. Biomolecules. 2019;9. [PMID: 31817161 DOI: 10.3390/biom9120824] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
11 Amin SA, Adhikari N, Jha T. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies? Pharmacological Research 2017;122:8-19. [DOI: 10.1016/j.phrs.2017.05.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
12 Kashif M, Andersson C, Hassan S, Karlsson H, Senkowski W, Fryknäs M, Nygren P, Larsson R, Gustafsson MG. In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index. Sci Rep 2015;5:14118. [PMID: 26392291 DOI: 10.1038/srep14118] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
13 Hu P, Sun M, Lu F, Wang S, Hou L, Yu Y, Zhang Y, Sun L, Yao J, Yang F, Wang C, Ma Z. Polymerized vorinostat mediated photodynamic therapy using lysosomal spatiotemporal synchronized drug release complex. Colloids Surf B Biointerfaces 2021;205:111903. [PMID: 34144323 DOI: 10.1016/j.colsurfb.2021.111903] [Reference Citation Analysis]
14 Hsu KC, Liu CY, Lin TE, Hsieh JH, Sung TY, Tseng HJ, Yang JM, Huang WJ. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach. Sci Rep 2017;7:3228. [PMID: 28607401 DOI: 10.1038/s41598-017-03417-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
15 Newbold A, Falkenberg KJ, Prince HM, Johnstone RW. How do tumor cells respond to HDAC inhibition? FEBS J 2016;283:4032-46. [PMID: 27112360 DOI: 10.1111/febs.13746] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 11.0] [Reference Citation Analysis]
16 Cai M, Hu J, Tian J, Yan H, Zheng C, Hu W. Novel hybrids from N-hydroxyarylamide and indole ring through click chemistry as histone deacetylase inhibitors with potent antitumor activities. Chinese Chemical Letters 2015;26:675-80. [DOI: 10.1016/j.cclet.2015.03.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
17 Amin SA, Adhikari N, Jha T. Structure–activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery. Future Medicinal Chemistry 2017;9:2211-37. [DOI: 10.4155/fmc-2017-0130] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
18 Létévé M, Gonzalez C, Moroy G, Martinez A, Jeanblanc J, Legastelois R, Naassila M, Sapi J, Bourguet E. Unexpected effect of cyclodepsipeptides bearing a sulfonylhydrazide moiety towards histone deacetylase activity. Bioorg Chem 2018;81:222-33. [PMID: 30153587 DOI: 10.1016/j.bioorg.2018.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Cheng MH, Wong YH, Chang CM, Yang CC, Chen SH, Yuan CL, Kuo HM, Yang CY, Chiu HF. B1, a novel HDAC inhibitor, induces apoptosis through the regulation of STAT3 and NF-κB. Int J Mol Med 2017;39:1137-48. [PMID: 28393178 DOI: 10.3892/ijmm.2017.2946] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
20 Mehta V, Athar M, Jha PC, Panchal M, Modi K, Jain VK. Efficiently functionalized oxacalix[4]arenes: Synthesis, characterization and exploration of their biological profile as novel HDAC inhibitors. Bioorg Med Chem Lett 2016;26:1005-10. [PMID: 26725026 DOI: 10.1016/j.bmcl.2015.12.044] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
21 Li Z, Chen Y, Tang M, Li Y, Zhu W. Regulation of DNA damage-induced ATM activation by histone modifications. GENOME INSTAB DIS 2020;1:20-33. [DOI: 10.1007/s42764-019-00004-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Shanmugam G, Rakshit S, Sarkar K. HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases. Transl Oncol 2021;16:101312. [PMID: 34922087 DOI: 10.1016/j.tranon.2021.101312] [Reference Citation Analysis]
23 Omidkhah N, Ghodsi R. NO-HDAC dual inhibitors. Eur J Med Chem 2022;227:113934. [PMID: 34700268 DOI: 10.1016/j.ejmech.2021.113934] [Reference Citation Analysis]
24 Taha TY, Aboukhatwa SM, Knopp RC, Ikegaki N, Abdelkarim H, Neerasa J, Lu Y, Neelarapu R, Hanigan TW, Thatcher GRJ, Petukhov PA. Design, Synthesis, and Biological Evaluation of Tetrahydroisoquinoline-Based Histone Deacetylase 8 Selective Inhibitors. ACS Med Chem Lett 2017;8:824-9. [PMID: 28835796 DOI: 10.1021/acsmedchemlett.7b00126] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
25 Guo C, Wang Q, Zhang X, Lu F, Sun M, Zeng P, Sun L, She L, Wang B, Zhang Y, Wang C, Ma Z, Yang F. Gelated Vorinostat with inner-lysosome triggered release for tumor-targeting chemotherapy. Colloids Surf B Biointerfaces 2020;194:111144. [PMID: 32535244 DOI: 10.1016/j.colsurfb.2020.111144] [Reference Citation Analysis]
26 Lin Y, Zhang H, Niu T, Tang ML, Chang J. Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone. Molecules 2020;25:E4494. [PMID: 33007982 DOI: 10.3390/molecules25194494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Nikolova T, Kiweler N, Krämer OH. Interstrand Crosslink Repair as a Target for HDAC Inhibition. Trends Pharmacol Sci 2017;38:822-36. [PMID: 28687272 DOI: 10.1016/j.tips.2017.05.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
28 Yang L, Liang Q, Shen K, Ma L, An N, Deng W, Fei Z, Liu J. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells. Biomedicine & Pharmacotherapy 2015;71:70-8. [DOI: 10.1016/j.biopha.2015.02.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
29 Banerjee S, Adhikari N, Amin SA, Jha T. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview. Eur J Med Chem 2019;164:214-40. [PMID: 30594678 DOI: 10.1016/j.ejmech.2018.12.039] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 8.8] [Reference Citation Analysis]
30 Micelli C, Rastelli G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today 2015;20:718-35. [PMID: 25687212 DOI: 10.1016/j.drudis.2015.01.007] [Cited by in Crossref: 109] [Cited by in F6Publishing: 93] [Article Influence: 15.6] [Reference Citation Analysis]
31 Grabarska A, Łuszczki JJ, Nowosadzka E, Gumbarewicz E, Jeleniewicz W, Dmoszyńska-Graniczka M, Kowalczuk K, Kupisz K, Polberg K, Stepulak A. Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells. J Cancer 2017;8:19-28. [PMID: 28123594 DOI: 10.7150/jca.16655] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
32 Mastoraki A, Schizas D, Charalampakis N, Naar L, Ioannidi M, Tsilimigras D, Sotiropoulou M, Moris D, Vassiliu P, Felekouras E. Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. Mol Diagn Ther 2020;24:175-84. [PMID: 32125662 DOI: 10.1007/s40291-020-00454-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Li Y, Li Z, Zhu WG. Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics. Curr Med Chem 2019;26:1328-50. [PMID: 28933282 DOI: 10.2174/0929867324666170921101947] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
34 Riedel SS, Neff T, Bernt KM. Histone profiles in cancer. Pharmacology & Therapeutics 2015;154:87-109. [DOI: 10.1016/j.pharmthera.2015.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
35 Peng X, Chen J, Li L, Sun Z, Liu J, Ren Y, Huang J, Chen J. Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. J Med Chem 2021;64:8447-73. [PMID: 34097389 DOI: 10.1021/acs.jmedchem.1c00413] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Dong Z, Cui H. Epigenetic modulation of metabolism in glioblastoma. Semin Cancer Biol 2019;57:45-51. [PMID: 30205139 DOI: 10.1016/j.semcancer.2018.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
37 Hrgovic I, Doll M, Pinter A, Kaufmann R, Kippenberger S, Meissner M. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism. Exp Dermatol 2017;26:194-201. [DOI: 10.1111/exd.13159] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
38 Tresckow B, Sayehli C, Aulitzky WE, Goebeler M, Schwab M, Braz E, Krauss B, Krauss R, Hermann F, Bartz R, Engert A. Phase I study of domatinostat (4 SC ‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies. Eur J Haematol 2018;102:163-73. [DOI: 10.1111/ejh.13188] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
39 Gupta R, Ambasta RK, Kumar P. Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders. Life Sci 2020;243:117278. [PMID: 31926248 DOI: 10.1016/j.lfs.2020.117278] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
40 Alshawli AS, Wurdak H, Wood IC, Ladbury JE. Histone deacetylase inhibitors induce medulloblastoma cell death independent of HDACs recruited in REST repression complexes. Mol Genet Genomic Med 2020;8:e1429. [PMID: 32720471 DOI: 10.1002/mgg3.1429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Rösler B, Wang X, Keating ST, Joosten LAB, Netea MG, van de Veerdonk FL. HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis. Clin Exp Immunol 2018;194:205-19. [PMID: 30069986 DOI: 10.1111/cei.13192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
42 Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S. SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Sarcoma 2018;2018:2068517. [PMID: 30473623 DOI: 10.1155/2018/2068517] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
43 Duan W, Li J, Inks ES, Chou CJ, Jia Y, Chu X, Li X, Xu W, Zhang Y. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor. J Med Chem 2015;58:4325-38. [PMID: 25906087 DOI: 10.1021/acs.jmedchem.5b00317] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 7.7] [Reference Citation Analysis]
44 Yang F, Zhao N, Ge D, Chen Y. Next-generation of selective histone deacetylase inhibitors. RSC Adv 2019;9:19571-83. [DOI: 10.1039/c9ra02985k] [Cited by in Crossref: 33] [Article Influence: 11.0] [Reference Citation Analysis]
45 Bao Y, Tong L, Song B, Liu G, Zhu Q, Lu X, Zhang J, Lu YF, Wen H, Tian Y, Sun Y, Zhu WG. UNG2 deacetylation confers cancer cell resistance to hydrogen peroxide-induced cytotoxicity. Free Radic Biol Med 2020;160:403-17. [PMID: 32649985 DOI: 10.1016/j.freeradbiomed.2020.06.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
46 Yu X, Li Z. Epigenetic deregulations in chordoma. Cell Prolif 2015;48:497-502. [PMID: 26256106 DOI: 10.1111/cpr.12204] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
47 Swierczynski S, Klieser E, Illig R, Alinger-Scharinger B, Kiesslich T, Neureiter D. Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases. Expert Opin Biol Ther. 2015;15:651-664. [PMID: 25766312 DOI: 10.1517/14712598.2015.1025047] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
48 Sui X, Zhu J, Zhou J, Wang X, Li D, Han W, Fang Y, Pan H. Epigenetic modifications as regulatory elements of autophagy in cancer. Cancer Letters 2015;360:106-13. [DOI: 10.1016/j.canlet.2015.02.009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
49 Zhang Q, Wang S, Chen J, Yu Z. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. Int J Med Sci 2019;16:424-42. [PMID: 30911277 DOI: 10.7150/ijms.30154] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
50 Liu C, Yang Q, Zhu Q, Lu X, Li M, Hou T, Li Z, Tang M, Li Y, Wang H, Yang Y, Wang H, Zhao Y, Wen H, Liu X, Mao Z, Zhu WG. CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis. Theranostics 2020;10:1758-76. [PMID: 32042335 DOI: 10.7150/thno.39013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
51 Le JM, Squarize CH, Castilho RM. Histone modifications: Targeting head and neck cancer stem cells. World J Stem Cells 2014; 6(5): 511-525 [PMID: 25426249 DOI: 10.4252/wjsc.v6.i5.511] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
52 Zhang Y, Wang Z, Huang Y, Ying M, Wang Y, Xiong J, Liu Q, Cao F, Joshi R, Liu Y, Xu D, Zhang M, Yuan K, Zhou N, Koropatnick J, Min W. TdIF1: a putative oncogene in NSCLC tumor progression. Signal Transduct Target Ther 2018;3:28. [PMID: 30345081 DOI: 10.1038/s41392-018-0030-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
53 Zhou J, Zhang C, Sui X, Cao S, Tang F, Sun S, Wang S, Chen B. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway. Invest New Drugs 2018;36:571-80. [PMID: 29504068 DOI: 10.1007/s10637-017-0552-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
54 Nickoloff JA, Jones D, Lee SH, Williamson EA, Hromas R. Drugging the Cancers Addicted to DNA Repair. J Natl Cancer Inst 2017;109. [PMID: 28521333 DOI: 10.1093/jnci/djx059] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 16.6] [Reference Citation Analysis]
55 Mrakovcic M, Kleinheinz J, Fröhlich LF. p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death. Int J Mol Sci 2019;20:E2415. [PMID: 31096697 DOI: 10.3390/ijms20102415] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
56 Yuan YG, Peng QL, Gurunathan S. Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer. Int J Nanomedicine 2017;12:6503-20. [PMID: 28919751 DOI: 10.2147/IJN.S136142] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 4.6] [Reference Citation Analysis]
57 Forés-Martos J, Catalá-López F, Sánchez-Valle J, Ibáñez K, Tejero H, Palma-Gudiel H, Climent J, Pancaldi V, Fañanás L, Arango C, Parellada M, Baudot A, Vogt D, Rubenstein JL, Valencia A, Tabarés-Seisdedos R. Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. Mol Autism 2019;10:17. [PMID: 31007884 DOI: 10.1186/s13229-019-0262-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
58 Li W, Sun Z. Mechanism of Action for HDAC Inhibitors-Insights from Omics Approaches. Int J Mol Sci 2019;20:E1616. [PMID: 30939743 DOI: 10.3390/ijms20071616] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
59 Cross JM, Blower TR, Kingdon ADH, Pal R, Picton DM, Walton JW. Anticancer Ruthenium Complexes with HDAC Isoform Selectivity. Molecules 2020;25:E2383. [PMID: 32455529 DOI: 10.3390/molecules25102383] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Li G, Tian Y, Zhu WG. The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy. Front Cell Dev Biol 2020;8:576946. [PMID: 33117804 DOI: 10.3389/fcell.2020.576946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
61 Schizas D, Mastoraki A, Naar L, Spartalis E, Tsilimigras DI, Karachaliou GS, Bagias G, Moris D. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. World J Gastroenterol 2018; 24(41): 4635-4642 [PMID: 30416311 DOI: 10.3748/wjg.v24.i41.4635] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
62 Yang F, Peng S, Li Y, Su L, Peng Y, Wu J, Chen H, Liu M, Yi Z, Chen Y. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities. Org Biomol Chem 2016;14:1727-35. [PMID: 26732459 DOI: 10.1039/c5ob02250a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
63 Schizas D, Mastoraki A, Naar L, Tsilimigras DI, Katsaros I, Fragkiadaki V, Karachaliou GS, Arkadopoulos N, Liakakos T, Moris D. Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role. Curr Med Chem 2020;27:6099-111. [PMID: 31309879 DOI: 10.2174/0929867326666190712160842] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
64 Zamora A, Vigueras G, Rodríguez V, Santana MD, Ruiz J. Cyclometalated iridium(III) luminescent complexes in therapy and phototherapy. Coordination Chemistry Reviews 2018;360:34-76. [DOI: 10.1016/j.ccr.2018.01.010] [Cited by in Crossref: 119] [Cited by in F6Publishing: 84] [Article Influence: 29.8] [Reference Citation Analysis]
65 Hrgovic I, Doll M, Kleemann J, Wang XF, Zoeller N, Pinter A, Kippenberger S, Kaufmann R, Meissner M. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer 2016;16:763. [PMID: 27716272 DOI: 10.1186/s12885-016-2807-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
66 Zagni C, Citarella A, Oussama M, Rescifina A, Maugeri A, Navarra M, Scala A, Piperno A, Micale N. Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker. Int J Mol Sci 2019;20:E945. [PMID: 30795625 DOI: 10.3390/ijms20040945] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
67 Mrakovcic M, Kleinheinz J, Fröhlich LF. Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53. Int J Mol Sci 2017;18:E1883. [PMID: 30563957 DOI: 10.3390/ijms18091883] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
68 Mamdani H, Jalal SI. Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope? Front Cell Dev Biol 2020;8:582370. [PMID: 33163495 DOI: 10.3389/fcell.2020.582370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
69 Marek M, Shaik TB, Duclaud S, Pierce RJ, Romier C. Large-Scale Overproduction and Purification of Recombinant Histone Deacetylase 8 (HDAC8) from the Human-Pathogenic Flatworm Schistosoma mansoni. In: Sarkar S, editor. Histone Deacetylases. New York: Springer; 2016. pp. 109-18. [DOI: 10.1007/978-1-4939-3667-0_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
70 Zhang S, Gong Z, Oladimeji PO, Currier DG, Deng Q, Liu M, Chen T, Li Y. A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma. Exp Hematol Oncol 2019;8:30. [PMID: 31788346 DOI: 10.1186/s40164-019-0153-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
71 Mekala JR, Naushad SM, Ponnusamy L, Arivazhagan G, Sakthiprasad V, Pal-Bhadra M. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer. Gene 2018;641:248-58. [PMID: 29038000 DOI: 10.1016/j.gene.2017.10.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
72 Wang P, Yuan D, Guo F, Chen X, Zhu L, Zhang H, Wang C, Shao C. Chromatin remodeling modulates radiosensitivity of the daughter cells derived from cell population exposed to low- and high-LET irradiation. Oncotarget 2017;8:52823-36. [PMID: 28881774 DOI: 10.18632/oncotarget.17275] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
73 Berghauser Pont LM, Spoor JK, Venkatesan S, Swagemakers S, Kloezeman JJ, Dirven CM, van der Spek PJ, Lamfers ML, Leenstra S. The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells. Genes Cancer 2014;5:445-59. [PMID: 25568669 DOI: 10.18632/genesandcancer.42] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
74 Zhang W, Li Q, Song C, Lao L. Knockdown of autophagy-related protein 6, Beclin-1, decreases cell growth, invasion, and metastasis and has a positive effect on chemotherapy-induced cytotoxicity in osteosarcoma cells. Tumor Biol 2015;36:2531-9. [DOI: 10.1007/s13277-014-2868-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
75 Bourguet E, Ozdarska K, Moroy G, Jeanblanc J, Naassila M. Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD). J Med Chem 2018;61:1745-66. [PMID: 28771357 DOI: 10.1021/acs.jmedchem.7b00115] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
76 Matjasic A, Popovic M, Matos B, Glavac D. Expression of LOC285758, a Potential Long Non-coding Biomarker, is Methylation-dependent and Correlates with Glioma Malignancy Grade. Radiol Oncol 2017;51:331-41. [PMID: 28959170 DOI: 10.1515/raon-2017-0004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
77 Shi Y, Wang Y, Jiang H, Sun X, Xu H, Wei X, Wei Y, Xiao G, Song Z, Zhou F. Mitochondrial dysfunction induces radioresistance in colorectal cancer by activating [Ca2+]m-PDP1-PDH-histone acetylation retrograde signaling. Cell Death Dis 2021;12:837. [PMID: 34489398 DOI: 10.1038/s41419-021-03984-2] [Reference Citation Analysis]
78 Zhang J, Wang J, Zhou Z, Park JE, Wang L, Wu S, Sun X, Lu L, Wang T, Lin Q, Sze SK, Huang D, Shen HM. Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors. Autophagy 2018;14:1043-59. [PMID: 30059277 DOI: 10.1080/15548627.2018.1447290] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
79 Ariffin JK, das Gupta K, Kapetanovic R, Iyer A, Reid RC, Fairlie DP, Sweet MJ. Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages. Antimicrob Agents Chemother 2015;60:1521-9. [PMID: 26711769 DOI: 10.1128/AAC.01876-15] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
80 Levinzon L, Madigan M, Nguyen V, Hasic E, Conway M, Cherepanoff S. Tumour Expression of Histone Deacetylases in Uveal Melanoma. Ocul Oncol Pathol 2019;5:153-61. [PMID: 31049320 DOI: 10.1159/000490038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
81 Mrakovcic M, Fröhlich LF. p53-Mediated Molecular Control of Autophagy in Tumor Cells. Biomolecules 2018;8:E14. [PMID: 29561758 DOI: 10.3390/biom8020014] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 16.0] [Reference Citation Analysis]
82 Dittmer J. Nuclear Mechanisms Involved in Endocrine Resistance. Front Oncol 2021;11:736597. [PMID: 34604071 DOI: 10.3389/fonc.2021.736597] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Kong YL, Pan BH, Liang JH, Zhu HY, Wang L, Xia Y, Wu JZ, Fan L, Li JY, Xu W. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia. Aging (Albany NY) 2020;12:16083-98. [PMID: 32855355 DOI: 10.18632/aging.103536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Zhou Z, Yang J, Kong A. Phytochemicals in Traditional Chinese Herbal Medicine: Cancer Prevention and Epigenetics Mechanisms. Curr Pharmacol Rep 2017;3:77-91. [DOI: 10.1007/s40495-017-0086-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
85 Mrakovcic M, Bohner L, Hanisch M, Fröhlich LF. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53. Int J Mol Sci 2018;19:E3952. [PMID: 30544838 DOI: 10.3390/ijms19123952] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
86 Abdelkarim H, Neelarapu R, Madriaga A, Vaidya AS, Kastrati I, Karumudi B, Wang YT, Taha TY, Thatcher GRJ, Frasor J, Petukhov PA. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors. ChemMedChem 2017;12:2030-43. [PMID: 29080240 DOI: 10.1002/cmdc.201700449] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
87 Song M, He G, Wang Y, Pang X, Zhang B. Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity. J Cancer 2016;7:1694-700. [PMID: 27698906 DOI: 10.7150/jca.15086] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]